Assessment of cardiomyopathy

Última revisión: 10 Jun 2025
Última actualización: 02 Apr 2025

Resumen

Diferenciales

Común

  • Idiopathic dilated cardiomyopathy
  • Myocarditis
  • Alcohol: dilated cardiomyopathy
Todos los datos

Infrecuente

  • Hypertrophic cardiomyopathy (HCM)
  • Idiopathic restrictive cardiomyopathy
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Brugada syndrome and other ion channelopathies
  • Conduction system disease
  • Mitochondrial disorders
  • Takotsubo syndrome
  • Peripartum: dilated cardiomyopathy
  • Tachycardia-induced: dilated cardiomyopathy
  • Amyloidosis: hypertrophic or restrictive cardiomyopathy
  • Haemochromatosis: restrictive or dilated cardiomyopathy
  • Fabry disease: hypertrophic or restrictive cardiomyopathy
  • Other lysosomal storage disease
  • Doxorubicin: dilated cardiomyopathy
  • Heavy metals/chemicals: dilated cardiomyopathy
  • Diabetes mellitus
  • Thyroid dysfunction: dilated cardiomyopathy
  • Acromegaly: hypertrophic or dilated cardiomyopathy
  • Noonan syndrome: hypertrophic cardiomyopathy
  • Lentiginosis: hypertrophic cardiomyopathy
  • Thiamine deficiency (wet beriberi): dilated cardiomyopathy
  • Friedreich's ataxia/muscular dystrophy: hypertrophic and dilated cardiomyopathy
  • Deficiency of iron, niacin, selenium, or vitamin D: dilated cardiomyopathy
  • Systemic lupus erythematosus: dilated cardiomyopathy
  • Endomyocardial fibrosis/Loeffler endocarditis (hypereosinophilic syndrome)
  • Sarcoidosis
  • Electrolyte disorders
Todos los datos

Colaboradores

Autores

Katie Linden, BMSc, MBChB

Cardiology Specialty Registrar

Belfast Health and Social Care Trust

Belfast

Northern Ireland

Divulgaciones

KL was reimbursed by Takeda UK Ltd., the manufacturer of Replagal for Fabry disease, for travel and accommodation for a leadership course. KL was reimbursed by Sanofi Aventis, the manufacturer of Genzyme for Fabry disease, for travel and accommodation for a conference. KL received a speaker fee from Sanofi Aventis, the manufacturer of Genzyme, for a talk on Fabry disease. There was no contractual right by Sanofi to control the content of this talk.

Alison Muir, MD

Consultant Cardiologist

Royal Victoria Hospital

Belfast Health and Social Care Trust

Belfast

UK

Divulgaciones

AM is an author of a reference cited in this topic.

Agradecimientos

KL and AM would like to gratefully acknowledge Dr Pascal McKeown, a previous contributor to this topic. PM is an author of a reference cited in this topic.

Revisores por pares

Lubna Choudhury, MB BCh, MD, MRCPI, FACC

Professor of Medicine

Division of Cardiology

Northwestern University

Chicago

IL

Divulgaciones

LC declares that she has no competing interests.

John Coltart, MD, FRCP, FACC, FESC, MRCS

Consultant Cardiologist

Cardio-thoracic Unit

Guy's and St Thomas' Hospital

London

UK

Declarações

JC declares that he has no competing interests.

Vaikom S. Mahadevan, MBBS, MRCP

Consultant Cardiologist

Manchester Royal Infirmary

Manchester

UK

Declarações

VSM declares that he has no competing interests.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Texto completo  Resumo

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024 Jun 4;149(23):e1239-311.Texto completo  Resumo

Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022 Jun;35(6):533-69.Texto completo  Resumo

American College of Radiology. ACR appropriateness criteria® Nonischemic myocardial disease with clinical manifestations (ischemic cardiomyopathy already excluded). May 2021 [internet publication].Texto completo  Resumo

British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Assessment of cardiomyopathy images
  • Diretrizes

    • Management of cardiomyopathies
    • Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Heart failure

    Heart failure: how can I help myself?

    Mais Folhetos informativos para os pacientes
  • Videos

    Third heart sound gallop

    Fourth heart sound gallop

    Mais vídeos
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal